July 2022

Factors Associated with Drug-free Remission at 5-year in Early Onset Axial Spondyloarthritis Patients: Data from the DESIR Cohort

Joint Bone Spine. 2022 doi.org/10.1016/j.jbspin.2022.105358

This study from Ruyssen-Witrand et al, highlights that the probability of being in drug free remission at 5-year in patients with recent onset of axSpA is low. The study was performed to investigate the possible association between demographic, clinical, biological and imaging characteristics and drug-free remission at 5 years.

Keywords:

Is the Risk of Infection Higher During Treatment with Secukinumab than with TNF-inhibitors? An Observational Study from the Nordic Countries

Rheumatology (Oxford). 2022 doi: 10.1093/rheumatology/keac358

Glintborg B et al, highlight in their recent research from the Nordic countries, that there is a low frequency of hospitalised infections during treatment with secukinumab or TNFi in patients with SpA and PsA. In clinical practice, secukinumab was found to double absolute risk of 1st year hospitalised infection compared with adalimumab, with the other TNFi treatments falling in between.

Keywords:

Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets with Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis

J Rheumatol. 2022 doi: 10.3899/jrheum.210906

Baseline disease activity, as measured by cDAPSA, predicts the achievement of treatment targets in DMARD-naïve patients post- apremilast treatment. To come to this conclusion Mease, et al.  analysed data from the PALACE 4 clinical trial which investigated apremilast in DMARD-naïve patients. 175 patients receiving 30mg apremilast from baseline with cDAPSA data available, were analysed.

Keywords:

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease‑modifying antirheumatic drugs: SPIRIT‑P1 and SPIRIT‑P2 3‑year results

Clin Rheumatol. 2022 doi: 10.1007/s10067-022-06218-8

In this investigation ixekizumab showed sustained efficacy in PsA therapy for up to three years in both monotherapy and combination with MTX or a csDMARD. Here, investigators set out to evaluate the three-year efficacy and safety of ixekizumab with and without csDMARD use in patients with active PsA.

Keywords:

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac375

This analysis found that patients with active PsA who receive treatment with guselkumab can achieve robust and sustained low disease activity or remission. In reaching this conclusion investigators sought to evaluate the efficacy of guselkumab for the treatment of active PsA through the use of composite indices.

Keywords:

Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac353

Here bimekizumab was associated with long-term reductions in disease activity and disease impact on patients with PsA. This investigation set out to evaluate the long-term effects of bimekizumab treatment on the key symptoms of PsA and the resulting impact on patient function and HRQoL.

Keywords:

Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection

Sci Rep. 2022 doi: 10.1038/s41598-022-11879-1

Established machine learning approaches, based on ligand similarity, identified previously unknown off-target interactions of baricitinib and tofacitinib, and adds to the evidence that these JAK inhibitors are promiscuous binders, and highlight the potential for repurposing.

Keywords:

Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study

Arthritis Res Ther. 2022 doi: 10.1186/s13075-022-02807-9

Retrospective, longitudinal, population-based study shows that despite an overall higher incidence of hospitalised infection (HI) in both elderly and older elderly patients compared to young patients, the risks of HI in patients exposed to targeted therapy versus MTX is not significantly increased.

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586

Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.

Keywords: